Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 270-096-9 | CAS number: 68411-04-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Potential absorption and bioavailability:
Study results on C.I. Direct Blue 264:
No adverse effects were reported in a non-guideline pilot study where the C.I. Direct Blue 264 was administered orally by gavage to 3 male and 3 female rats per group, in daily doses of 0, 100, 500 or 1000 mg/kg bw/day for 14 days. There were no toxicologically significant effects on survival, clinical examinations, body weight, food intake and water intake. The only finding at clinical examinations was blue feces color, which was observed for all treated animals and is due to the color of the test substance. Findings clearly related to the oral administration of the test compound were noticed at necropsy only in the intestinal tract in males starting at 100 mg/kg bw/day and in females starting at 500 mg/kg bw/day. Changes in content, blue, was observed in small intestine, cecum and large intestine. No other organ was colored. Single males of this study displayed pale discoloration of the kidney. These observations are not necessarily indicative for a systemic effect on the kidneys induced by a test compound because they could have developed perimortally as a consequence of interindividual differences in the grade/status of exsanguination. Occasionally these gross observations do not have any histopathologic correlate at all or may show an equivocal histopathologic finding of the kidneys. To investigate potential uptake and excretion of the compound the color of the urine was investigated photometrically in this study. Urine has be collected during a period of about 16 hours at room temperature from all animals of the control and high dose groups near the end of the study. The color of the urine did not differ between these groups. Furthermore, photometry of urinary samples gave no evidence that the test substance was excreted with the urine. Based on the photometric urine analysis and the necropsy findings in this 14 day pilot study specifically designed to investigate potential compound uptake, distribution and excretion, no systemic absorption was observed.
Conclusion:
Overall, from the data of these repeated dose studies, there is no evidence of a toxicological relevant absorption of C.I. Direct Blue 264.
Acute toxicity:
Study results:
In an acute oral toxicity study in female rats a LD50 > 5000 mg/kg bw and a LD50 > 2000 mg/kg bw for acute dermal toxicity in male and female rats was found for C.I. Direct Blue 264.
Skin irritation/corrosion and eye irritation:
Study results:
In a skin irritation/corrosion study and an eye irritation study C.I. Direct Blue 264 was not irritating.
Conclusion:
No skin and eye irritation was observed.
Genotoxicity:
Study results:
An Ames test, an in-vitro MNT and a HPRT test with C.I. Direct Blue 264 were negative.
Conclusion:
All available genotoxicity tests were negative.
Subacute and reproductive toxicity:
Study results:
In a pilot 14 day oral gavage study with C.I. Direct Blue 264 in rats a NOAEL >1000 mg/kg bw/day was found. No toxicological relevant findings were observed on the following parameters: survival, clinical examination, body weight, food and water intake and necropsy.
In an OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity in Rodents) the test item Direct Blue 264 (CAS 68411-04-1) was administered daily in graduated doses to 3 groups of test animals, one dose level per group for a treatment period of 90 days. The following doses were evaluated: 0 (control), 250, 500, or 1000 mg/kg body weight.
No test-item related mortality was observed and no adverse effects of the test item were found for male and female clinical observations, functional observations, body weight development, food consumption, hormone analysis, sperm parameters, haematology and coagulation, clinical biochemistry, urinalysis, gross macroscopic findings at necropsy, organ weights and histopathology in all treated dose groups.
The no observed adverse effect level (NOAEL) of Direct Blue 264 in this study is considered to be 1000 mg/kg body weight/day.
In an OECD TG 414 study no effects of Direct Blue 264 on pregnant females and foetuses were found at dose levels up to 1000 mg/kg body weight/day. The NOAEL (No Observed Adverse Effect Level) for both maternal toxicity and foetal toxicity of Direct Blue 264 in this study is considered to be 1000 mg/kg body weight/day (the highest dose tested).
Note:
The national Occupational Exposure Limit in Germany for chemically and biologically inert dust is 10 mg/m3 for inhalable and 2.5 mg/m3 for respirable dust (TRGS900).
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Potential absorption and bioavailability:
Study results on C.I. Direct Blue 264:
No adverse effects were reported in a non-guideline pilot study where the C.I. Direct Blue 264 was administered orally by gavage to 3 male and 3 female rats per group, in daily doses of 0, 100, 500 or 1000 mg/kg bw/day for 14 days. There were no toxicologically significant effects on survival, clinical examinations, body weight, food intake and water intake. The only finding at clinical examinations was blue feces color, which was observed for all treated animals and is due to the color of the test substance. Findings clearly related to the oral administration of the test compound were noticed at necropsy only in the intestinal tract in males starting at 100 mg/kg bw/day and in females starting at 500 mg/kg bw/day. Changes in content, blue, was observed in small intestine, cecum and large intestine. No other organ was colored. Single males of this study displayed pale discoloration of the kidney. These observations are not necessarily indicative for a systemic effect on the kidneys induced by a test compound because they could have developed perimortally as a consequence of interindividual differences in the grade/status of exsanguination. Occasionally these gross observations do not have any histopathologic correlate at all or may show an equivocal histopathologic finding of the kidneys. To investigate potential uptake and excretion of the compound the color of the urine was investigated photometrically in this study. Urine has be collected during a period of about 16 hours at room temperature from all animals of the control and high dose groups near the end of the study. The color of the urine did not differ between these groups. Furthermore, photometry of urinary samples gave no evidence that the test substance was excreted with the urine. Based on the photometric urine analysis and the necropsy findings in this 14 day pilot study specifically designed to investigate potential compound uptake, distribution and excretion, no systemic absorption was observed.
Conclusion:
Overall, from the data of these repeated dose studies, there is no evidence of a toxicological relevant absorption of C.I. Direct Blue 264.
Acute toxicity:
Study results:
In an acute oral toxicity study in female rats a LD50 > 5000 mg/kg bw and a LD50 > 2000 mg/kg bw for acute dermal toxicity in male and female rats was found for C.I. Direct Blue 264.
Skin irritation/corrosion and eye irritation:
Study results:
In a skin irritation/corrosion study and an eye irritation study C.I. Direct Blue 264 was not irritating.
Conclusion:
No skin and eye irritation was observed.
Genotoxicity:
Study results:
An Ames test, an in-vitro MNT and a HPRT test with C.I. Direct Blue 264 were negative.
Conclusion:
All available genotoxicity tests were negative.
Subacute and reproductive toxicity:
Study results:
In a pilot 14 day oral gavage study with C.I. Direct Blue 264 in rats a NOAEL >1000 mg/kg bw/day was found. No toxicological relevant findings were observed on the following parameters: survival, clinical examination, body weight, food and water intake and necropsy.
In an OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity in Rodents) the test item Direct Blue 264 (CAS 68411-04-1) was administered daily in graduated doses to 3 groups of test animals, one dose level per group for a treatment period of 90 days. The following doses were evaluated: 0 (control), 250, 500, or 1000 mg/kg body weight.
No test-item related mortality was observed and no adverse effects of the test item were found for male and female clinical observations, functional observations, body weight development, food consumption, hormone analysis, sperm parameters, haematology and coagulation, clinical biochemistry, urinalysis, gross macroscopic findings at necropsy, organ weights and histopathology in all treated dose groups.
The no observed adverse effect level (NOAEL) of Direct Blue 264 in this study is considered to be 1000 mg/kg body weight/day.
In an OECD TG 414 study no effects of Direct Blue 264 on pregnant females and foetuses were found at dose levels up to 1000 mg/kg body weight/day. The NOAEL (No Observed Adverse Effect Level) for both maternal toxicity and foetal toxicity of Direct Blue 264 in this study is considered to be 1000 mg/kg body weight/day (the highest dose tested).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
